Address
Duchnicka 3
bud. 16, wejście A
01-796 Warszawa
Poland
Contact
Paweł Dębski+48507054427
pawel.debski@scopefluidics.com
Website
Massively parallel AST
BacterOMIC provides fastest access to complete information to direct targeted antibiotic therapies.
BacterOmic delivers complete information on phenotypic antibiotic susceptibility of bacterial pathogens: MIC values for all antibiotics and synergies between up to 20 combinations. It enables precision therapies already after the first test.
BacterOMIC provides MIC values for 2.5-10 times more agents than competitors, eliminating the need of additional testing, reducing cost and time.
- Antimicrobial stewardship
- Microbial diagnostics
- Infection prevention
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Research
- Validation
- Market entry
- Marketed product
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- Co-develop
- Joint Venture
- Sell
- License
- Outsource
Funding organisation:
Infectious disease area:
Geographic origin:
We seek strategic partnership with a global diagnostic systems supplier that can best leverage the market value of Bacteromic, offering complete AST information for targeted antibiotics therapies, within established workflow and test-price structure.
BacterOmic is a med-tech startup developing automated AST to provide doctors MIC values for all clinically relevant antibiotics from a single test
BacterOmic is part of Scope Fluidics Group, that develops also point-of-care molecular Dx system – PCR|ONE featuring 15-minute time-to-result and high multiplexing capacity. The first PCR|ONE panel detects and characterizes MRSA infections.
